Finadyne Solution


Finadyne 50 mg/ml solution for injection

Qualitative and quantitative composition

Active substance
Flunixin (as Flunixin Meglumine ) 50 mg
Excipients: Phenol (preservative) 5 mg
For a full list of excipients, see section "Pharmaceutical Particulars".

Pharmaceutical form

Solution for injection

Clinical particulars

Target species
Cattle, pigs and horses.

Indications for use 

In Cattle: For the control of acute inflammation associated with respiratorydisease. Finadyne has also been shown to have some benefit in the treatment of experimentalacute bovine pulmonary emphysema (Fog Fever). Finadyne Solution may be used as adjunctivetherapy in the treatment of acute mastitis. 

In Horses: For the alleviation of inflammation and pain associated with musculo-skeletal disorders.
For the alleviation of visceral pain associated with colic in the horse. 

In Pigs: For use as an adjunctive therapy inthe treatment of swine respiratory diseases.

Do not exceed the stated dose or the duration of treatment. Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is hypersensitivity to the product. Do not use the product within 48 hours before expected parturition in cows. Do not administer to pregnant mares. Do not administer to pregnant sows, gilts at mating and in breeding boars.

Special warnings for each target species
Non-steroidal, anti-inflammatory drugs are not permitted under the rules of Racing and under rules covering other competitive events. The Royal College of Veterinary Surgeons has given advice to the Veterinary Profession regarding the use of anti-inflammatory drugs in competing horses. It states that “if a veterinarian recommends the discontinuation of any such drug not less than eight days before racing, he should feel sure that he has catered for all but the most exceptional case”. Do not exceed the recommended dose or duration of treatment

Special precautions for use
Avoid intra-arterial injection.
NSAIDS are known to have the potential to delay parturition through a tocolytic effect by inhibiting prostaglandins that are important in signalling the initiation of parturition. The use of the product in the immediate post-partum period may interfere with uterine involution and expulsion of foetal membranes resulting in retained placentae. See also section "Use during pregnancy and lactation".
Use in any animal less than 6 weeks of age or inaged animals may involve additional risk. If such use cannot be avoided animals may require a reduced dosage and careful clinical management. Do not use in hypovolaemic animals except in the case of endotoxaemia or septic shock. Itis preferable that NSAIDs which inhibit prostaglandin synthesis are not administered to animals undergoing general anaesthesia until fully recovered. The cause of colic should be determined and treated with concurrent therapy. The product should not beused in piglets weighing less than 6 kg.

Operator warnings:

Avoid contact with skin or eyes. In case of skin contact, wash exposed area with water. In case of eye contact, wash eyes thoroughly with clean water and seek medical advice. Take care against accidental self injection. Wash hands after use.

Adverse reactions
Flunixin meglumine is a non-steroidal anti-inflammatory drug (NSAID). Untoward effects include gastro-intestinal irritation, ulceration and, in dehydrated or hypovolaemic animals, potential for renal damage. In pigs transient irritation may occur at the injection site, this resolves spontaneously within 14 days.

Use during pregnancy, lactation or lay
The product may be used in pregnant and lactating cattle. The product should only be administered within the first 36 hours post-partum following a benefit/risk assessment performed by the responsible veterinarian and treated animals should be monitored for retained placentae. Do not use in pregnant mares or pregnant sows. Safety studies in pregnantmares and pregnant sows have not been conducted.

Do not administer other NSAIDs concurrently orwithin 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects. Concurrent administration of potentially nephrotoxic drugs should be avoided.

Amounts to be administered and administration route 


2 ml per 45 kg bodyweight (equivalent to 2.2 mg flunixin per kg) administeredintravenously. Repeat as necessary at 24 hour intervals for up to 5 consecutive days.


By intravenous injection for musculo-skeletal disorders at the following rate:
1 ml per 45 kg bodyweight (1.1 mg flunixin/kg) once daily for up to 5 days according to clinical response.
By intravenous injection for colic at the following rate: 1ml per 45 kg bodyweight (1.1 mg flunixin/kg) repeated once or twice if colic recurs. For the treatment of endotoxaemia or septic shock associated with gastric torsion and with other conditions in which the circulation of blood to the gastro-intestinal tract is compromised: 0.25 mg/kg every 6-8 hours, by intravenous injection.


2 ml per 45 kg bodyweight (equivalent to 2.2 mg flunixin/kg) once by intramuscular injection, in the neck, in conjunction with appropriate antimicrobial therapy. The injection volume should be limited to a maximum of 5 ml per injection site. An appropriately graduated syringe must be used to allow accurate administration of the required dose volume. This is particularly important when injecting small volumes. When intramuscular injection isused, the dose should be divided between two injection sites on either side of the neck. In order to prevent excessive broaching of the rubber stopper, it is not recommended that the stopper is broached more than 25 times.

Overdosage studies in the targetspecies have shown the product to be well-tolerated. Flunixin meglumine is a non-steroidal anti-inflammatory drug.

Overdosage is associated with gastrointestinal toxicity. Concurrent use of nephrotoxic drugs should be avoided.

Withdrawal periods
Animals must not be slaughtered for human consumption during treatment.
Cattle: 5 days from the last treatment.
Horses: 7 days from the last treatment.
Pigs: 22 days from the last treatment.
Milk for human consumption must not be taken during treatment. Milk for human consumption may only be taken from cattle after 24 hours from the last treatment.

Pharmacological particulars

Flunixin meglumine is a potent, non-steroidal, non-narcotic analgesic with anti-inflammatory, antiendotoxic and anti-pyretic activities.

Pharmaceutical particulars

Phenol, Diethanolamine, Disodium Edetate dihydrate, Sodium Formaldehyde sulfoxylate dihydrate, Propylene Glycol, Hydrochloric acid 2.0N and Water for injection.

Major incompatibilities
Do not administer other NSAIDs concurrently orwithin 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects. Concurrent administration of potential nephrotoxic drugs should be avoided.

Shelf life
3 years.
Following withdrawal of the first dose, use within 28 days.

Discard unused material.

Special precautions for storage
Do not store above 25°C. Do not freeze.

Immediate packaging

Pack Sizes: 50 ml and 100 ml vials.
Containers: Clear Type I glass vials, molded.
Closures: Chlorobutyl rubber stopper with flip-off cap.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Marketing Authorisation Holder (if different from distributor)

Marketing authorisation number 

Vm 01708/4582.

Date of the first authorisation or date of renewal 

27 August 2007.

Date of revision of the text

July 2012.

Any other information 

For animal treatment only. Keep out of the sight and reach of children.

Legal category


GTIN (Global Trade Item No)

Finadyne Solution 1x50ml:


Finadyne Solution 1x100ml: